Stephen Yoder News Today

BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones

Haley -- in a surprise to many -- made out the GOP to be the wicked earmark kings of Congress, while admitting that Democrats were relatively frugal.

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring BOSTON,MA, July 18, 2023 - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company...

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring ...

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep Due to New Non-Clinical Safety Findings From 13-week Toxicology Study BOSTON,MA,... | June 21, 2023

Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase ...

By Adriano Marchese Pieris Pharmaceuticals shares were halted in premarket trading after its partner AstraZeneca decided to discontinue and cease dosing in...

BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

FinancialContent fully hosted finance channel

Operator: Good day, ladies and gentlemen. And welcome to the Pieris Pharmaceuticals to host First Quarter 2023 Investor Call.